PolyPid (PYPD) Q2 2025 earnings summary

Executive summary

• Achieved transformational results in the SHIELD II phase III trial for D-PLEX 100, showing a 58% reduction in surgical site infections and a 62% reduction in severe wound infections, with a strong safety profile and no increase in serious adverse events.

• NDA submission for D-PLEX 100 is expected in early 2026, leveraging Fast Track and Breakthrough Therapy designations.

• Advanced a novel long-acting GLP-1 delivery platform targeting metabolic diseases, obesity, and diabetes, aiming for improved patient compliance and outcomes.

• Substantial interest from commercial partners and healthcare professionals due to D-PLEX 100's clinical benefits and cost-saving potential.

• Strengthened leadership with the appointment of Dr. Nurit Tweezer-Zaks as Chief Medical Officer to support regulatory and commercial milestones.

Financial highlights

• Cash and cash equivalents of $17.4M and short-term deposits of $12M as of June 30, 2025, totaling $29.5M, up from $15.6M at year-end 2024.

• Q2 2025 net loss of $10M ($0.78/share) vs. $6.3M ($1.25/share) in Q2 2024; six-month net loss of $18.2M ($1.48/share) vs. $12.7M ($2.62/share) in 2024.

• R&D expenses rose to $6.2M in Q2 2025 from $4.8M in Q2 2024, and to $12.3M for the six months from $9.8M year-over-year.

• G&A expenses increased to $2.5M in Q2 2025 from $1.1M in Q2 2024, mainly due to non-cash performance-based awards and PSU vesting.

• Marketing and business development expenses were $0.7M in Q2 2025, up from $0.3M in Q2 2024.

Outlook and guidance

• NDA submission for D-PLEX 100 planned for early 2026, with pre-NDA meeting with FDA by end of 2025 and European MAA submission to follow.

• Current cash runway expected to fund operations well into 2026.

• Ongoing commercial preparations and partnership discussions for D-PLEX 100 in the U.S. and Europe.

• Continued development of GLP-1 delivery platform for obesity and diabetes indications, with plans for clinical collaboration with major industry players.